Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Optimizing randomized phase II trials assessing tumor progression.

Andrew Stone1, Catherine Wheeler, Kevin Carroll

  • 1AstraZeneca, Alderley Park, Macclesfield, Cheshire, SK10 4TG, UK. andrew.stone@astrazeneca.com

Contemporary Clinical Trials
|June 30, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Bilateral Deficit in Exercise and Sport: A Narrative Review.

Journal of strength and conditioning research·2026
Same author

Clinicopathologic and Molecular Characteristics of Merkel Cell Polyomavirus Positive T-Cell Lymphoproliferative Disorders.

The American journal of surgical pathology·2026
Same author

The Children's Urgent Reduction of Forearm Fractures in the Emergency Department (CURFFED) project : a national prospective trainee-led collaborative audit of practice.

Bone & joint open·2026
Same author

Multicentre evaluation of teicoplanin prescribing and monitoring in the UK and Ireland: the TUcK-SHOP study.

The Journal of antimicrobial chemotherapy·2026
Same author

Evaluating Sibeprenlimab in IgA Nephropathy - Rationale and Baseline Data from the VISIONARY Trial.

Kidney international reports·2025
Same author

Sibeprenlimab in IgA Nephropathy - Interim Analysis of a Phase 3 Trial.

The New England journal of medicine·2025
Same journal

Effectiveness of clinical trial recruitment strategies in a safety-net hospital.

Contemporary clinical trials·2026
Same journal

Are older adult research participants representative of the general population? Results from 19 clinical studies at one academic research center.

Contemporary clinical trials·2026
Same journal

Multi-site feasibility of a web-based and telephone navigation intervention to connect lung cancer caregivers in community oncology settings with resources: Protocol for the WF-2301CD Caregiver Oncology Needs Evaluation Tool (CONNECT) trial.

Contemporary clinical trials·2026
Same journal

Rationale and design of a CArdiac rehabilitation program on the prevention of CardioTOXicity in breast Cancer patients undergoing treatment with anthracyclines and/or trastuzumab (CARPTOX-BC) trial: A randomized, active control group, open-label trial.

Contemporary clinical trials·2026
Same journal

Evaluating clinical outcomes of using Undermyfork mobile app with Dexcom G7: Protocol for CGM-Undermyfork randomized controlled trial.

Contemporary clinical trials·2026
Same journal

Outcomes of dyadic recruitment in the promoting re-engagement in meaningful activity (PRIMA) trial.

Contemporary clinical trials·2026
See all related articles

New methods improve phase II oncology trials for cytostatic therapies. These approaches optimize progression-free survival endpoints, enhancing clinical development decisions by minimizing assessment bias.

Area of Science:

  • Oncology
  • Clinical Trial Design
  • Biostatistics

Background:

  • Cytostatic therapies in oncology trials necessitate new evaluation methods beyond tumor shrinkage.
  • Traditional phase II trial designs face challenges with cytostatic agents that slow tumor growth.

Purpose of the Study:

  • To propose methodological solutions for enhancing phase II oncology trial decision-making.
  • To address biases in progression-free survival endpoints for cytostatic therapies.
  • To optimize the use of progression data in phase II randomized trials.

Main Methods:

  • Discussing design and analysis solutions for progression endpoints.
  • Implementing time-independent methods to minimize assessment bias.
  • Exploring features to maximize information yield in phase II settings.

Related Experiment Videos

Main Results:

  • Proposed methods minimize bias in progression endpoint timing and interpretation.
  • Utilizing all available progression data is more effective than fixed time-point analyses.
  • Frequent progression assessments beyond routine clinical practice offer limited additional benefit.

Conclusions:

  • Optimized progression endpoints enhance phase II clinical evaluation decisions.
  • Time-independent and comprehensive data analysis methods are crucial.
  • Methodological advancements support the development of cytostatic cancer therapies.